Trust me, trust no one.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Don't miss the Psycheceutical team this weekend as @HarringtonKevin, @KaiaRoman and @ZappyZapolin take the stage at the Cannadelic Miami Conference to share the latest progress and updates in #psychedelicmedicine.
— Psycheceutical (@psycheceutical) January 31, 2023
Event details and schedule: https://t.co/df7Zh9Kfyp pic.twitter.com/7V0ies42m8
Dive into the potential future of psychedelic medicine — without the trip — as @WSJhealth explores how new drug development could benefit those who are currently excluded from psychedelic treatment for safety or professional reasons.
— Psycheceutical (@psycheceutical) January 30, 2023
Read: https://t.co/yS0NdvwxdT pic.twitter.com/2uIi5iMTAR
$BWVI looking great! Psychecuetical RM'd to go public, FINRA will get around to completing the name change anytime now. Great IP Great Management:
Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD
Press Release | 01/26/2023
MIAMI, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge treatments for mental health, has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for the first ketamine topical intended for treating post-traumatic stress disorder (PTSD).
The provisional patent application describes ketamine formulations for topical administration and related methods of treating PTSD, utilizing NeuroDirect™ non-systemic drug delivery technology. This delivery system is designed to topically distribute neuro-active compounds to the back of the neck for immediate action on a dense population of brain nerve endings. These novel ketamine formulations, and methods of treatment, are being developed to reduce the side effects caused by prior formulations, such as hallucinations, nausea, lethargy, and toxicity, but more importantly to also reduce pain and symptoms of PTSD.
“PTSD can be a serious mental health disorder, with no known effective therapeutic solutions currently available. Millions of people suffer each year,” said Chad Harman, Chief Executive Officer of Psycheceutical. “But there is new hope. This patent application supports Psycheceutical's ongoing drug development plans for its revolutionary NeuroDirect™ topical delivery system that we believe has the potential to provide new solutions and treatments for PTSD and other mental health conditions.”
PTSD is a common mental health condition affecting hundreds of millions of people worldwide, with symptoms ranging from mild to severe. PTSD is commonly interconnected with other mental health conditions, such as anxiety, depression, and substance abuse disorder. People who suffer from PTSD also have a higher risk of suicide.
“Psycheceutical is driven to provide new hope for this debilitating disorder by employing cutting-edge technologies for the patients who need it most,” said Dr. Julian Bailes, Chief Medical Officer of Psycheceutical. “We look forward to improving current mental health treatments while progressing the capabilities of the psychedelic pharmaceutical category.”
NeuroDirect™ for Non-Systemic Delivery
Psycheceutical’s NeuroDirect™ non-systemic delivery technology is protected by several patents and pending applications, and is designed to deliver neuro-active compounds directly into the nerve tissue via topical application at the back of the neck. This delivery system is intended to enable immediate and sustained delivery, safe dosage control, and consistent results, while avoiding the systemic side effects of psychedelic compounds such as hallucinations, nausea and vomiting. NeuroDirect™ is designed to be administered through telehealth or at home instead of a clinical setting, greatly lowering the cost of care for each patient, ensuring that these life-saving treatments are cheap and available to anyone suffering from mental health disorders or central nervous system diseases.
About Psycheceutical Bioscience, Inc.
Psycheceutical Bioscience, Inc. is seeking to develop cutting-edge delivery technologies to support and advance the safe and effective delivery of psychedelic pharmaceutical medicines. Powered by a team of FDA drug development veterans, biotechnology experts, and the top minds in the psychedelic space, Psycheceutical is on a mission to develop, improve and commercialize its precision dosing technologies to provide affordable, life-saving treatments to anyone suffering from mental health disorders or central nervous system diseases. Learn more at Psycheceutical.com.
Forward-Looking Statements:
Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These uncertainties include, but are not limited to, (i) general market growth for and acceptance of psychedelic-inspired medicines, (ii) capital and credit availability and market volatility, (iii) general economic conditions, (iv) governmental approvals and compliance with regulations, (v) product research and development and clinical trial risks, (vi) incorrect underlying assumptions, and (vii) our future business development, results of operations, and financial condition. These statements generally can be identified using forward-looking words such as “will,” “may,” “should,” “could,” "intend,” “estimate,” “plan,” "anticipate,” "expect,” “believe,” “potential” or “continue,” or the negative thereof or similar variations. All information provided in this press release is as of the date of this press release, and we undertake no duty to update such information, except as required under applicable law.
Contact:
Kaia Roman, VP, Strategy & Communications
kaia.roman@psycheceutical.com
https://www.otcmarkets.com/stock/BWVI/news/Psycheceutical-Bioscience-Provisional-Patent-Application-for-Novel-Ketamine-Topical-for-the-Treatment-of-PTSD?id=387770
Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD
Press Release | 01/26/2023
MIAMI, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge treatments for mental health, has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for the first ketamine topical intended for treating post-traumatic stress disorder (PTSD).
The provisional patent application describes ketamine formulations for topical administration and related methods of treating PTSD, utilizing NeuroDirect™ non-systemic drug delivery technology. This delivery system is designed to topically distribute neuro-active compounds to the back of the neck for immediate action on a dense population of brain nerve endings. These novel ketamine formulations, and methods of treatment, are being developed to reduce the side effects caused by prior formulations, such as hallucinations, nausea, lethargy, and toxicity, but more importantly to also reduce pain and symptoms of PTSD.
“PTSD can be a serious mental health disorder, with no known effective therapeutic solutions currently available. Millions of people suffer each year,” said Chad Harman, Chief Executive Officer of Psycheceutical. “But there is new hope. This patent application supports Psycheceutical's ongoing drug development plans for its revolutionary NeuroDirect™ topical delivery system that we believe has the potential to provide new solutions and treatments for PTSD and other mental health conditions.”
PTSD is a common mental health condition affecting hundreds of millions of people worldwide, with symptoms ranging from mild to severe. PTSD is commonly interconnected with other mental health conditions, such as anxiety, depression, and substance abuse disorder. People who suffer from PTSD also have a higher risk of suicide.
“Psycheceutical is driven to provide new hope for this debilitating disorder by employing cutting-edge technologies for the patients who need it most,” said Dr. Julian Bailes, Chief Medical Officer of Psycheceutical. “We look forward to improving current mental health treatments while progressing the capabilities of the psychedelic pharmaceutical category.”
NeuroDirect™ for Non-Systemic Delivery
Psycheceutical’s NeuroDirect™ non-systemic delivery technology is protected by several patents and pending applications, and is designed to deliver neuro-active compounds directly into the nerve tissue via topical application at the back of the neck. This delivery system is intended to enable immediate and sustained delivery, safe dosage control, and consistent results, while avoiding the systemic side effects of psychedelic compounds such as hallucinations, nausea and vomiting. NeuroDirect™ is designed to be administered through telehealth or at home instead of a clinical setting, greatly lowering the cost of care for each patient, ensuring that these life-saving treatments are cheap and available to anyone suffering from mental health disorders or central nervous system diseases.
About Psycheceutical Bioscience, Inc.
Psycheceutical Bioscience, Inc. is seeking to develop cutting-edge delivery technologies to support and advance the safe and effective delivery of psychedelic pharmaceutical medicines. Powered by a team of FDA drug development veterans, biotechnology experts, and the top minds in the psychedelic space, Psycheceutical is on a mission to develop, improve and commercialize its precision dosing technologies to provide affordable, life-saving treatments to anyone suffering from mental health disorders or central nervous system diseases. Learn more at Psycheceutical.com.
Forward-Looking Statements:
Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These uncertainties include, but are not limited to, (i) general market growth for and acceptance of psychedelic-inspired medicines, (ii) capital and credit availability and market volatility, (iii) general economic conditions, (iv) governmental approvals and compliance with regulations, (v) product research and development and clinical trial risks, (vi) incorrect underlying assumptions, and (vii) our future business development, results of operations, and financial condition. These statements generally can be identified using forward-looking words such as “will,” “may,” “should,” “could,” "intend,” “estimate,” “plan,” "anticipate,” "expect,” “believe,” “potential” or “continue,” or the negative thereof or similar variations. All information provided in this press release is as of the date of this press release, and we undertake no duty to update such information, except as required under applicable law.
Contact:
Kaia Roman, VP, Strategy & Communications
kaia.roman@psycheceutical.com
Catch Psycheceutical's @ChadHarmanCEO talking psychedelic medicine, the company's two patented drug delivery technologies and the future of mental health treatment with @mattbrownza on The Matt Brown Show.
— Psycheceutical (@psycheceutical) January 26, 2023
Watch or listen: https://t.co/H3a74OGIOI pic.twitter.com/uGwSGwZgeh
A new double-blind, placebo-controlled study saw "significant reductions" in depressive symptoms after a single dose of psilocybin paired with supportive counseling.@PsyPost: https://t.co/3nw20eway0 pic.twitter.com/OuN1NdJPG8
— Psycheceutical (@psycheceutical) January 25, 2023
2023 is the year for psycheceutical! Looking forward to wha's coming!
Much coming for Sona, if one follows all the seed planted over the last couple of years, fruition time is coming 2023. Looking forward to the next update!
Factually right, right right right. Doesnt matter if a statement says no when the fact is all the Toronto locations are ebitda postive.
Also the company is still waiting on FINRA, which should be any day to make that final corporate changeover. Otherwise the Snakes and Lattes staff aren't going to be discussing Amfil with customers. Once the corporate change over happens and as they grow, there will be more of a corporate feel in brand and training etc. However, even once we are huge and mutli dollars on a senior exchange, the servers will STILL NOT be talking to customers about the corporate side of things.
So instead of the statements that have zero impact and connection to the customer experience, let's here more on the actual experience around what Snakes and Lattes actually is: A Game Board Cafe
Looking forward to the next update!
$FUNN
Data says they opened 8 locations and only closed one, the smallest one. The experience also shows the business model needs a certain size location and this is what goes in to the current searches. So consider is a test site for a smaller model.
Looking forward to the next update
$FUNN
Give Roger a call like I said....
Snakes and Lattes started in Toronto, it wouldn't be a pubco if it wasn't for these locations.
Most companies start a few local locations before expanding. The Toronto locations are all EBITDA positive.
It's where it all began. They are expanding and will continue to expand with the right locations where the pathway to success can be readily seen.
Looking forward to the next update!
$FUNN
2023 is going to be amazing!
Members of the Psycheceutical team (@ChadHarmanCEO, @DrJulianBailes, @KaiaRoman, @ZappyZapolin) attending "Open Our Minds Together: The Healing Power of Psychedelics with Governor Rick Perry" in Dallas, TX as special "psychedelic ambassadors" for the evening. 🍄 pic.twitter.com/W9pj9xtRKI
— Psycheceutical (@psycheceutical) January 21, 2023
Exactly, I certainly read and understood the OP, and 100% agree with your response. I was expanding on your statement in the same style. :)
You can go in to a Coca Cola manufacturing plant and ask general line employees on their awareness on all their product lines and the corporate entity. They won't know much at all.
Ask a young server at a restaurant about the corporate side of the company... laughable.
Next time I fill up at Chevron, I'll get the inside scoop on corporate actions and stock recommendations from the attendant.
Weekend time, and we know business is getting good! 3 years of solid growth in the mils!! Lets go!
It's going to be an incredible year for team @Psycheceutical and all of the #psychedelicmedicine industry. Excited and humbled to be sharing the promising future of #mentalhealth treatment alongside none other than @ABCSharkTank original, @HarringtonKevin.
— Zappy Zapolin (@ZappyZapolin) January 17, 2023
Peace. Zappy pic.twitter.com/mINEQp2OqS
$BWVI Heating up! Long way to go and the roll out about to begin, FINRA work getting done to change symbol post RM
Interview with CEO Chad Harmon so good!
Looking great! The interview with the CEO was awesome. Getting it done, FINRA will change.
Clearly, any information posting concerning the previous company (The Shell Blue Waters we RM'd into) is not up to
speed on what is actually happening (and has been happening for over a year now) as psycheceutical.com is going through
all the regulatory steps to come out the surviving member on the RM. FINRA taking a long time but been there any day,
and away we go and never look back.
www.psycheceutical.com
Heating up nicely! Loved collecting all the cheaps thanks! Ready to roll, been a bit since the last PR I expect the company to drop some solid meat soon enough!
I think this is by far the best and most important line in the PR:
After two quarters in FY 2023, Snakes & Lattes can give guidance to shareholders that the company does anticipate another significant increase in revenues for FY 2023 ending June 30th, 2023.
This is great, the locations are EBITDA positive and the company can turn profitable this year.
Looking forward to the next update!
$FUNN
Snakes & Lattes Inc. Provides Shareholders With a 2022 Year End Summary as Well as a Glimpse Ahead & Some Guidance for 2023
Press Release | 01/17/2023
TORONTO, ON, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Snakes & Lattes Inc. (OTC: FUNN) takes a look back at 2022 and will briefly touch on a few items that are in store for 2023.
2022 was a pivotal year for Snakes & Lattes Inc. Most significant is the continued upward trend in revenue generation. The entire calendar year consistently beat 2021 in quarter to quarter comparison with overall revenues up over 200% for the 2021-2022 Fiscal Year (FY) which runs July to June.
Coming off an extremely challenging past few years for the restaurant and entertainment industry; the company posted approximately $2M for FY 2021 and approximately $6M FY 2022. (Despite All Toronto locations being closed all of Jan and most of Feb 2022)
After two quarters in FY 2023, Snakes & Lattes can give guidance to shareholders that the company does anticipate another significant increase in revenues for FY 2023 ending June 30th, 2023.
A couple of highlights:
2022 was a banner year for our Tempe location. Tempe broke all historical records for the company; bringing in over $3M for calendar 2022.
Special events and programming throughout all venues took a massive upswing this year and almost every event hosted was sold out across all venues.
The company issued $150,000 USD in convertible notes throughout the entirety of 2021 at a fixed price of .015 and raised $0 in convertible notes throughout all of 2022. The public float of the company (cumulative from inception in 1985 with no recapitalizations in its history) is currently 509,071,305 as of January 2023 and was 490,400,624 as of December 2021.
As the company has seen a nice return in patronage and increasing revenues, the value of the implemented cost improvement measures allows higher margins to be secured. While the pandemic had a major impact on the company and industry in general, it also created focus. From this focus, a better experience for the customer has been created. In turn, a higher dollar average amount for customer invoices. This focus also created a pathway to profitability for which many of our locations are now achieving. Where we cannot see the path, we make the decision to divest ourselves of unprofitable ventures. We saw this with the Guelph location and made the decision to close in September of 2022. The company expects to replace the Guelph location with at least one newer and better location this year. The other three locations inside Toronto are trending well, EBITDA positive, and expected to continue on an upward trajectory.
One of the major highlights for Snakes & Lattes in 2022 was winning the annual TAGIE awards held in Chicago. Winning the ‘Most Innovative Retailer’ category up against other industry giants such as Disney (Star Wars), Barnes and Noble, F.A.O. Schwarz, and Hasbro Pulse. The TAGIE awards, (Toy And Game International Excellence Awards) founded in 2008, and presented by People of Play (POP) is a prestigious international event that, being in its 15th year and part of POP Week, brought in over 30,000 people from 115 countries. This event honors the best and brightest innovators, designers, retailers, suppliers and marketers in the toy and game industry.
The conference and award ceremony once again brought Snakes & Lattes Inc. into the light with many industry key people, and the networking and contacts that came from it will be invaluable going forward. In 2021, LEGO took the category, but this year, Snakes & Lattes proudly cemented itself as the winner of the Most Innovative Retailer of 2022.
“2022 was a pivotal year for Snakes & Lattes. We have gotten past the pandemic era and are beginning to thrive again. Fiscal year 2023 will be three straight years of solid revenue growth. We are doing so in a more efficient and focused manner. The TAGIE award was a huge honor for us, and will lead to great opportunities in the future. We still have a number of locations we are looking at, as well as the funding to open them, all the while keeping minimal dilution to the company and shareholders in mind. We are being careful in finding the right location to maximize the chances of success. We need to easily see the profitability potential for the location prior to investing time, effort and money into it. However we have some targets that are currently being negotiated and worked on,” said Snakes & Lattes Inc. Founder Ben Castanie.
We are still working towards securing the 2 new locations which are already fully funded on friendly terms to the company amongst many other exciting things. News will be made available once either an LOI or Definitive Agreement has been signed.
There have been a number of ongoing projects that the company intends to provide status updates on throughout 2023 as milestones and completions are accomplished.
As always, a big thank you to all our supporters, loyal customers and dedicated staff. We continue to serve in honor to create the best possible experience for our patrons. The future of Snakes and Lattes looks bright as we continue to improve, add on new locations, take on lucrative strategic partnerships and build our brand. Creating memorable and quality human interactive experiences keeps us going, and at all times we keep the mission of ‘Snakes and Lattes locations coast to coast’ at the forefront of our strategy.
See you at Snakes & Lattes!
About Snakes & Lattes Inc.
Snakes & Lattes Inc. currently operates 7 tabletop gaming bars and cafes: 3 located in Toronto, Ontario, Canada, 1 in Tempe, Arizona, 1 in Tucson, Arizona, 1 in Provo, Utah, and 1 in Chicago, Illinois. The company is in the process of expanding throughout North America. Snakes & Lattes Inc. was the first board game bar and cafe in North America, and is believed to be the largest in the world. Our board game cafes have the largest circulating public library of board games in North America for customers to choose from.
For more information on Snakes & Lattes Inc., please visit the website at: www.snakesandlattes.com.
For further updates from Snakes & Lattes Inc., please follow us on Twitter @SnakesandLattes.
Safe Harbor Statement
This news release contains statements that involve expectations, plans or intentions (such as those relating to future business or financial results, new features or services, or management strategies) and other factors discussed from time to time in the Company's OTC Market or Securities and Exchange Commission filings. These statements are forward-looking and are subject to risks and uncertainties, so actual results may vary materially. You can identify these forward-looking statements by words such as "may," "should,", "will", "expect," "anticipate," "believe," "estimate," "confident," "intend," "plan" and other similar expressions. Our actual results, such as the Company's ability to finance, complete and consolidate acquisition of IP, assets and operating companies, could differ materially from those anticipated in these forward-looking statements as a result of certain factors not within the control of the company such as a result of various factors, including future economic, competitive, regulatory, and market conditions. The company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.
Contact:
Ben Castanie
Snakes & Lattes Inc.
Telephone: (416) 500-2911
Email: ben@snakesandlattes.com
Learn more about psychedelic medicine with @NPR as they explore the growing interest and scientific research behind the renewed focus on psychedelic therapy for mental health treatment.
— Psycheceutical (@psycheceutical) January 16, 2023
Read the article:https://t.co/TIhUWKHX2z pic.twitter.com/HbI7PH5q3f
Nice buy! Looking forward to what is coming here!
$BWVI
On a roll! Lets keep it going, loaded up nicely and a long way to go on the upside!
Chad Harman, CEO of Psycheceutical, Sits in the Investor Hotseat on January 12th https://t.co/jV0pelE9Z3
— Psychedelic Invest (@psyinvest) January 12, 2023
Nice Day $SSFT!
Looking forward to more
Don't miss Psycheceutical's @ChadHarmanCEO LIVE in the Investor Hotseat this Thurs, 1/12 at 4pm ET as he joins @psyinvest host @DustinRLaw to talk about our cutting-edge delivery technologies for psychedelic-pharmaceutical medicines.https://t.co/U8RsFzMFg1 pic.twitter.com/yHGIpyr7py
— Psycheceutical (@psycheceutical) January 11, 2023
NEWS: Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer
Press Release | 01/10/2023
MIAMI, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc.(OTCPK: BWVI) ("Psycheceutical" or the "Company"), a bioscience company dedicated to developing cutting-edge brain delivery technologies for the next generation of mental health treatments, today announced that Dr. Julian Bailes has accepted the role of Chief Medical Officer and will also join the company’s Board of Directors. Bailes will continue to assist in the strategy, direction, and execution of the company’s clinical and technological development of its patented dosing technologies, with the goal of providing the safe and effective delivery of psychedelic pharmaceutical compounds.
"Psycheceutical’s Board believes that given his extensive expertise in both clinical care and research, Dr. Bailes is ideally suited to oversee the company’s medical affairs as we prepare to initiate clinical trials for our novel drug delivery systems later this year,” said Chad Harman, CEO of Psychececutical.
Bailes is an esteemed leader in the fields of neurosurgery and traumatic brain injuries. His expertise in the understanding of CTE was showcased in the 2015 film “Concussion,” starring Will Smith, where Bailes was portrayed by actor Alec Baldwin. He is the Chairman of the Department of Neurosurgery, Co-Director of the Neurological Institute at NorthShore University Health System, and Clinical Professor of Neurosurgery at the University of Chicago Pritzker School of Medicine. Bailes is also a Senior Advisor to the NFL Head, Neck, and Spine Committee and a member of the NFLPA Mackey-White Health and Safety Committee and the Chair of the Medical Advisory Board of Pop Warner Football, Inc.
“I’ve been continually impressed by the assemblage of Psycheceutical’s first-class team, the opportunities they have identified, as well as the progress they’ve made in furthering their brain drug development technology in such a short time,” said Dr. Julian Bailes, Chief Medical Officer of Psycheceutical. “Disease and mental health states such as depression, traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), post-traumatic stress disorder (PTSD), and anxiety could significantly be improved upon with further advances in brain delivery technology. I decided to further my involvement by joining the Board of Directors to help advance this critical technology as soon as possible to hopefully improve the mental health crisis we’re experiencing around the world.”
As Chief Medical Advisor for Psycheceutical, Bailes will continue his role overseeing the company’s Medical Advisory Board, a team of top medical specialists guiding the research and development of the company’s next-generation dosing and delivery technology. The Medical Advisory Board works in tandem with the company’s scientific team in identifying and reviewing outstanding molecules to bring through the drug discovery and development process to clinical application.
With his addition to the Board of Directors, Bailes will provide strategic focus on advancing the company’s mission to bring its innovative drug delivery technologies to market, ensure the company is adhering to the policies and regulations set forth by the DEA and FDA, and offer guidance on future partnerships and the acquisition of intellectual property.
About Psycheceutical Bioscience, Inc.
Psycheceutical Bioscience, Inc. is developing cutting-edge technologies to advance the safe and effective delivery of psychedelic pharmaceutical medicines. Powered by a team of FDA drug development veterans, biotechnology experts, and the top minds in the psychedelic space, Psycheceutical is on a mission to commercialize its precision dosing technologies to provide affordable, life-saving treatments to anyone suffering from mental health disorders or central nervous system diseases. Learn more at Psycheceutical.com.
Forward-Looking Statements:
Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These uncertainties include, but are not limited to, (i) general market growth for and acceptance of psychedelic-inspired medicines, (ii) capital and credit availability and market volatility, (iii) general economic conditions, (iv) governmental approvals and compliance with regulations, (v) product research and development and clinical trial risks, (vi) incorrect underlying assumptions, and (vii) our future business development, results of operations, and financial condition. These statements generally can be identified using forward-looking words such as "will," “may,” “should,” “could,” "intend,” “estimate,” “plan,” "anticipate,” "expect,” “believe,” “potential” or “continue,” or the negative thereof or similar variations. All information provided in this press release is as of the date of this press release, and we undertake no duty to update such information, except as required under applicable law.
Contact:
Kaia Roman, VP, Strategy & Communications
kaia.roman@psycheceutical.com
A new @JAMA_current study predicts that the majority of states will have legalized psychedelic medicine by 2034 to 2037.
— Psycheceutical (@psycheceutical) January 9, 2023
Read in @Benzinga: https://t.co/u6wT72tc8X pic.twitter.com/zPRECVKLt6
"At the center of the psychedelic experience is the sense that you are not the center of it all—and that is liberating, exhilarating, and possibly life-changing."#expandconsciousness
— Zappy Zapolin (@ZappyZapolin) January 10, 2023
Peace. Zappyhttps://t.co/mPmaCjyUOF
A new era is coming.
— Zappy Zapolin (@ZappyZapolin) January 2, 2023
Peace. Zappyhttps://t.co/n1wsXn5sr9#psychedelicmedicine #consciousness #mentalhealth
I'm often asked what it's like to be a Psychedelic Concierge, so here's a peek behind the scenes! Catch my latest article in @benzinga.https://t.co/JPI0qOP1gz
— Zappy Zapolin (@ZappyZapolin) December 30, 2022
Peace. Zappy pic.twitter.com/B9DRsbo98y
Principal Medical Advisor, Dr. Julian E. Bailes on the importance of #mentalhealth, the state of mental health in society today, and treatment options available from a medical physician's perspective. #mentalhealthmatters #psycheceutical pic.twitter.com/o5lCi1I5SU
— Psycheceutical (@psycheceutical) December 30, 2022
Snakes and Lattes will do well in 2023. Solid positive trend for the locations and more to come.
$FUNN
Possible for sure, but just more important to continue the upward trends and have all locations turn positive for overall profitability.
Lots coming for next year!
$FUNN
The emergence of psychedelic medicine as treatment for #mentalhealth and #addiction has become so mainstream that it's headlining in @BocaMag! Honored to share my knowledge - there are so many who are suffering and in need this very help. https://t.co/0NvrCTfwxu
— Zappy Zapolin (@ZappyZapolin) December 27, 2022
Peace. Zappy pic.twitter.com/48UJvm1epD